<DOC>
	<DOCNO>NCT01512420</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety second-line Tarceva ( erlotinib ) patient previously treat advanced non-small cell lung cancer confirm wild-type epidermal growth factor receptor ( EGFR ) gene . The aim study identify baseline clinical demographic patient characteristic prognostic factor relate overall survival second-line Tarceva treatment . Data collect eligible patient 2 year .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor ( EGFR ) Gene ( WILT )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm locally advanced metastatic nonsmall cell lung cancer ( NSCLC ) Patients know wildtype EGFR gene ; patient unknown EGFR mutation status allow fulfil follow criterion : squamous cell carcinoma lung cancer histology , current smoker , former smoker stop smoke less 10 year ago total &gt; 15 packyears smoke Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients fail one prior chemotherapy regimen eligible secondline treatment Tarceva Current treatment investigational drug participation another investigational study Severe uncontrolled systemic disease , active infection , concomitant malignancy second primary malignancy except situ carcinoma cervix adequately treat basal cell carcinoma skin Clinically active interstitial lung disease Recent myocardial infarction unstable angina Progressive uncontrolled brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>